Thank you, Mr. Chair.
This question is for Dr. Ali, initially.
I don't know if you had a chance to listen in on the first hour of our meeting, but I'm particularly interested in the matter of a grant from the Government of Canada to the Medicago vaccine manufacturer, and Ms. Waite, either of you are welcome to weigh in on this in the short time we have.
This grant was given to make sure Canada had domestic production capacity but also to ensure that we could meet our COVAX obligations. In the last meeting, I asked public officials about this, and they said that the fact that the WHO had disallowed the Covifenz vaccine for international emergency use would not affect the Government of Canada's contribution to COVAX.
Subsequent to that, media reports said that the minister had confirmed that in fact it would affect our contribution to COVAX.
I see this as a failure of due diligence on the part of the Government of Canada to ensure that when it is providing a grant to a company that is partially owned by a tobacco company—in this case, Philip Morris—it does its due diligence to ensure that the product is available for emergency use outside our borders. I'm wondering if you could comment on that situation.